280 related articles for article (PubMed ID: 34535965)
1. BRAF V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases.
Kobayashi S; Takahashi S; Nomura S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N; Taniguchi H; Yoshino T
Cancer Med; 2021 Oct; 10(20):6998-7011. PubMed ID: 34535965
[TBL] [Abstract][Full Text] [Related]
2. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes of Resected BRAF V600E Mutant Colorectal Liver Metastases: A Multicenter Retrospective Cohort Study in Japan.
Kobayashi S; Takahashi S; Takahashi N; Masuishi T; Shoji H; Shinozaki E; Yamaguchi T; Kojima M; Gotohda N; Nomura S; Yoshino T; Taniguchi H
Ann Surg Oncol; 2020 Sep; 27(9):3307-3315. PubMed ID: 32661852
[TBL] [Abstract][Full Text] [Related]
4. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study.
Javed S; Benoist S; Devos P; Truant S; Guimbaud R; Lièvre A; Sefrioui D; Cohen R; Artru P; Dupré A; Bachet JB; de la Fouchardière C; Ploquin A; Turpin A
World J Surg Oncol; 2022 Apr; 20(1):131. PubMed ID: 35461290
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S
Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866
[TBL] [Abstract][Full Text] [Related]
8. Genomic and prognostic heterogeneity among RAS/BRAF
Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
[TBL] [Abstract][Full Text] [Related]
9. Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis.
Gau L; Ribeiro M; Pereira B; Poirot K; Dupré A; Pezet D; Gagnière J
Eur J Surg Oncol; 2021 Nov; 47(11):2722-2733. PubMed ID: 34099355
[TBL] [Abstract][Full Text] [Related]
10. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
Margonis GA; Boerner T; Bachet JB; Buettner S; Moretto R; Andreatos N; Sartore-Bianchi A; Wang J; Kamphues C; Gagniere J; Lonardi S; Løes IM; Wagner D; Spallanzani A; Sasaki K; Burkhart R; Pietrantonio F; Pikoulis E; Pawlik TM; Truant S; Orlandi A; Pikouli A; Pella N; Beyer K; Poultsides G; Seeliger H; Aucejo FN; Kornprat P; Kaczirek K; Lønning PE; Kreis ME; Wolfgang CL; Weiss MJ; Cremolini C; Benoist S; D'Angelica M
Ann Surg; 2023 Sep; 278(3):e540-e548. PubMed ID: 36453261
[TBL] [Abstract][Full Text] [Related]
11. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
[TBL] [Abstract][Full Text] [Related]
12. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
[TBL] [Abstract][Full Text] [Related]
14. Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases.
Kobayashi S; Nakamura Y; Taniguchi H; Odegaard JI; Nomura S; Kojima M; Sugimoto M; Konishi M; Gotohda N; Takahashi S; Yoshino T
Ann Surg Oncol; 2021 Aug; 28(8):4744-4755. PubMed ID: 33393041
[TBL] [Abstract][Full Text] [Related]
15. Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy.
Datta J; Narayan RR; Goldman DA; Chatila WK; Gonen M; Strong J; Balachandran VP; Drebin JA; Kingham TP; Jarnagin WR; Schultz N; Kemeny NE; D'Angelica MI
Ann Surg; 2022 Nov; 276(5):e474-e482. PubMed ID: 33214457
[TBL] [Abstract][Full Text] [Related]
16. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases.
Pikoulis E; Margonis GA; Andreatos N; Sasaki K; Angelou A; Polychronidis G; Pikouli A; Riza E; Pawlik TM; Antoniou E
Anticancer Res; 2016 Sep; 36(9):4805-11. PubMed ID: 27630332
[TBL] [Abstract][Full Text] [Related]
19. RAS Mutation Is Associated with Decreased Survival in Patients Undergoing Repeat Hepatectomy for Colorectal Liver Metastases.
Denbo JW; Yamashita S; Passot G; Egger M; Chun YS; Kopetz SE; Maru D; Brudvik KW; Wei SH; Conrad C; Vauthey JN; Aloia TA
J Gastrointest Surg; 2017 Jan; 21(1):68-77. PubMed ID: 27334313
[TBL] [Abstract][Full Text] [Related]
20. The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial.
Bolhuis K; Bond MJG; Van Amerongen MJ; Komurcu A; Chapelle T; Dejong CHC; Engelbrecht MRW; Gerhards MF; Grünhagen DJ; van Gulik TM; Hermans JJ; De Jong KP; Kazemier G; Klaase JM; Kok NFM; Leclercq WKG; Liem MSL; van Lienden KP; Molenaar IQ; Neumann UP; Patijn GA; Rijken AM; Ruers TM; Verhoef C; de Wilt JHW; May AM; Punt CJA; Swijnenburg RJ;
Eur J Cancer; 2023 Apr; 183():49-59. PubMed ID: 36801606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
